Investigators present results of Phase 2 trial of ibrutinib+rituximab in high-risk CLL patients

At median follow up of 14 months, 32/40 patients continue on therapy (16/20 with del17p or TP53 mutation) without disease progression

Partial Response (PR) : 87%; Complete Response (CR) : 8%; Overall Response Rate (ORR): 95%

ORR in 20 patients with del17p or TP53 mutation was 90% (16 PR, 2 CR)

Grade 3 AE: mucositis (n=1), peripheral neuropathy (n=1)

Significantly improved QOL after 6 months.